All In Biotech

Drug Trial Radar · NCT01431287

Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

A Randomised, Double-blind, Parallel Group Study to Assess the Efficacy and Safety of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5 µg / 5 µg; 5 µg / 5 µg) (Delivered by the Respimat® Inhaler) Compared With the Individual Components (2.5 µg and 5 µg Tiotropium, 5 µg Olodaterol) (Delivered by the Respimat® Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD) [TOnado TM 2]

Last checked: Nov 19, 2026Latest source record: Jul 16, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,539 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,539

Actual

Start

Sep 2011

Primary completion

Nov 2013

Study completion Nov 2013

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Sep 9, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components (tiotropium, olodaterol) (delivered by the RESPIMAT Inhaler) in patients with COPD.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • tiotropium + olodaterolDrug

    fixed dose combination

  • tiotropium + olodaterolDrug

    fixed dose combination

  • tiotropiumDrug

    low dose or high dose

  • tiotropiumDrug

    low dose or high dose

  • olodaterolDrug

    one dose only

  • RespimatDevice

    Respimat inhaler

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (0-3h) Response on Day 169Time frame: 1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 169
  2. Trough FEV1 Response on Day 170Time frame: 1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 23 h and at 23 h 50 min after inhalation of study medication on Day 170
  3. Saint George's Respiratory Questionnaire (SGRQ) Total Score on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274).Time frame: Day 169

Locations

240 sites in 24 countries. Site status is shown where the registry gives one.

  • 1237.6.01106 Boehringer Ingelheim Investigational Site

    Greer, California

  • 1237.6.01120 Boehringer Ingelheim Investigational Site

    Fort Collins, Colorado

  • 1237.6.01131 Boehringer Ingelheim Investigational Site

    Danbury, Connecticut

  • 1237.6.01117 Boehringer Ingelheim Investigational Site

    Waterbury, Connecticut

  • 1237.6.01118 Boehringer Ingelheim Investigational Site

    DeLand, Florida

  • 1237.6.01126 Boehringer Ingelheim Investigational Site

    Tampa, Florida

  • 1237.6.01109 Boehringer Ingelheim Investigational Site

    Winter Park, Florida

  • 1237.6.01134 Boehringer Ingelheim Investigational Site

    Atlanta, Georgia

  • 1237.6.01107 Boehringer Ingelheim Investigational Site

    Couer d'Alene, Idaho

  • 1237.6.01110 Boehringer Ingelheim Investigational Site

    Lafayette, Louisiana

  • 1237.6.01128 Boehringer Ingelheim Investigational Site

    Baltimore, Maryland

  • 1237.6.01130 Boehringer Ingelheim Investigational Site

    North Dartmouth, Massachusetts

  • 1237.6.01104 Boehringer Ingelheim Investigational Site

    Minneapolis, Minnesota

  • 1237.6.01116 Boehringer Ingelheim Investigational Site

    Plymouth, Minnesota

  • 1237.6.01121 Boehringer Ingelheim Investigational Site

    St Louis, Missouri

  • 1237.6.01123 Boehringer Ingelheim Investigational Site

    St Louis, Missouri

  • 1237.6.01129 Boehringer Ingelheim Investigational Site

    Henderson, Nevada

  • 1237.6.01136 Boehringer Ingelheim Investigational Site

    Marlton, New Jersey

  • 1237.6.01108 Boehringer Ingelheim Investigational Site

    Albuquerque, New Mexico

  • 1237.6.01127 Boehringer Ingelheim Investigational Site

    Bayside, New York

  • 1237.6.01139 Boehringer Ingelheim Investigational Site

    Great Neck, New York

  • 1237.6.01135 Boehringer Ingelheim Investigational Site

    Charlotte, North Carolina

  • 1237.6.01114 Boehringer Ingelheim Investigational Site

    Cincinnati, Ohio

  • 1237.6.01102 Boehringer Ingelheim Investigational Site

    Columbus, Ohio

  • 1237.6.01115 Boehringer Ingelheim Investigational Site

    Oklahoma City, Oklahoma

  • 1237.6.01101 Boehringer Ingelheim Investigational Site

    Philadelphia, Pennsylvania

  • 1237.6.01113 Boehringer Ingelheim Investigational Site

    East Providence, Rhode Island

  • 1237.6.01122 Boehringer Ingelheim Investigational Site

    Charleston, South Carolina

  • 1237.6.01132 Boehringer Ingelheim Investigational Site

    Greenville, South Carolina

  • 1237.6.01137 Boehringer Ingelheim Investigational Site

    Greenville, South Carolina

  • 1237.6.01111 Boehringer Ingelheim Investigational Site

    Spartanburg, South Carolina

  • 1237.6.01105 Boehringer Ingelheim Investigational Site

    Union, South Carolina

  • 1237.6.01138 Boehringer Ingelheim Investigational Site

    Killeen, Texas

  • 1237.6.01124 Boehringer Ingelheim Investigational Site

    McKinney, Texas

  • 1237.6.01112 Boehringer Ingelheim Investigational Site

    Richmond, Virginia

  • 1237.6.01133 Boehringer Ingelheim Investigational Site

    Richmond, Virginia

  • 1237.6.01125 Boehringer Ingelheim Investigational Site

    Spokane, Washington

  • 1237.6.01103 Boehringer Ingelheim Investigational Site

    Tacoma, Washington

  • 1237.6.43006 Boehringer Ingelheim Investigational Site

    Feldbach, Austria

  • 1237.6.43005 Boehringer Ingelheim Investigational Site

    Gänserndorf, Austria

Showing 40 of 240 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.